AbbVie Inc (NYSE:ABBV)

79.76
Delayed Data
As of Mar 22
 -1.48 / -1.82%
Today’s Change
75.77
Today|||52-Week Range
107.25
-13.48%
Year-to-Date
4 Blockbuster Drug Launches to Watch in 2019
6:46pm / MotleyFool.com - Paid Partner Content
AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA
Mar 20 / Zacks.com - Paid Partner Content
3 Bargain Stocks You Can Buy Today
2:02pm / MotleyFool.com - Paid Partner Content
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
Mar 18 / Zacks.com - Paid Partner Content
Where Will AbbVie Be in 10 Years?
9:12am / MotleyFool.com - Paid Partner Content
2 Things Investors Are Missing About AbbVie
Mar 17 / MotleyFool.com - Paid Partner Content
This is Why AbbVie (ABBV) is a Great Dividend Stock
Mar 22 / Zacks.com - Paid Partner Content
Roche Receives EC Approval for Label Expansion of Hemlibra
Mar 14 / Zacks.com - Paid Partner Content
Better Buy: AbbVie vs. Eli Lilly
Mar 21 / MotleyFool.com - Paid Partner Content
3 Dividend Aristocrats to Buy and Hold Forever
Mar 14 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close81.24
Today’s open80.78
Day’s range79.69 - 81.99
Volume4,992,843
Average volume (3 months)6,905,366
Market cap$117.6B
Data as of 4:00pm ET, 03/22/2019

Growth & Valuation

Earnings growth (last year)-265.71%
Earnings growth (this year)+9.67%
Earnings growth (next 5 years)+7.00%
Revenue growth (last year)+16.08%
P/E ratio21.8
Price/Sales4.35
Price/Book--

Competitors

 Today’s
change
Today’s
% change
SNYSanofi-1.17-2.58%
AZNAstraZeneca-0.36-0.84%
GSKGlaxoSmithKline+0.01+0.02%
LLYEli Lilly and Co-0.01-0.01%
Data as of 4:01pm ET, 03/22/2019

Financials

Next reporting dateApril 25, 2019
EPS forecast (this quarter)$2.05
Annual revenue (last year)$32.8B
Annual profit (last year)$5.7B
Net profit margin17.27%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chairman &
Chief Executive Officer
Richard A. Gonzalez
Vice Chairman &
President
Michael E. Severino
Corporate headquarters
North Chicago, Illinois

Forecasts